BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...first biosimilar win in EU The European Commission approved Zercepac from Accord Healthcare Ltd. and Shanghai Henlius Biotech Inc....
...and Co. Mirati Therapeutics Inc. Amgen Inc. Merck & Co. U.S. Food and Drug Administration (FDA) Truvian Sciences Inc. Ascletis Pharma Inc. Shanghai Henlius Biotech Inc. Accord...
BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

...AG (see “Alliance Advancing Unbranded Hyperimmune Globulin Product” ). Chinese trio join to develop antibody Shanghai Henlius Biotech Inc....
...at https://www.biocentury.com/coronavirus . Elizabeth S. Eaton, Staff Writer remdesivir, GS-5734 Gilead Sciences Inc. CSL Ltd. Takeda Pharmaceutical Co. Ltd. ADMA Biologics Inc. Shanghai Henlius Biotech Inc. covid-19 cov19count cov19count...
BioCentury | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

...first, the number of listings nearly doubled, despite a four-month lapse in new listings midyear. Shanghai Henlius Biotech Inc....
BioCentury | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

...2019 listings included CStone Pharmaceuticals Co. Ltd. (HKEX:2616), CanSino Biologics Inc. (HKEX:6185), Mabpharm Ltd. (HKEX:2181), Shanghai Henlius Biotech Inc....
BioCentury | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

...NASDAQ:HCM) said it would wait for better market conditions before moving forward with its application. Shanghai Henlius Biotech Inc....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Corp. (KOSDAQ:244460) 09/20/19 $25.4 $234.5 $218.3 -7% Exagen Inc. (NASDAQ:XGN) 09/18/19 $58.0 $168.5 $186.4 11% Shanghai Henlius Biotech Inc....
BioCentury | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

...of its proposed range. Parent company Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) said Shanghai Henlius Biotech Inc....
...development through IND submission to Phase III testing in combination with other agents. Hongjiang Li, Staff Writer Shanghai Henlius Biotech Inc. Programmed...
BioCentury | Sep 13, 2019
Financial News

Sept. 12 Financial Quick Takes: IPOs from 10x, SpringWorks; plus Shanghai Henlius, Fate and more

...Phase III testing for desmoid tumors. Hong Kong IPO could give Shanghai Henlius $3.7B valuation Shanghai Henlius Biotech Inc....
...June by Domain, Jean-Philippe Herbeuval, Kurma Partners, Idinvest Partners and Erganeo. BioCentury Staff 10x Genomics Inc. Fate Therapeutics Inc. Shanghai Henlius Biotech Inc. Kurma...
BioCentury | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

...Exchanges and Clearing Ltd., which operates the exchange. Shanghai Henlius refiles for Hong Kong IPO Shanghai Henlius Biotech Inc....
...of Oxford. A Phase I trial is slated for 2020. BioCentury Staff ADC Therapeutics S.A. Genmab A/S GNS Healthcare Inc. Shanghai Henlius Biotech Inc. SinoMab...
BioCentury | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

...Wave" ). Four other companies have active applications for listing on the biotech chapter including Shanghai Henlius Biotech Inc....
Items per page:
1 - 10 of 23
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...first biosimilar win in EU The European Commission approved Zercepac from Accord Healthcare Ltd. and Shanghai Henlius Biotech Inc....
...and Co. Mirati Therapeutics Inc. Amgen Inc. Merck & Co. U.S. Food and Drug Administration (FDA) Truvian Sciences Inc. Ascletis Pharma Inc. Shanghai Henlius Biotech Inc. Accord...
BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

...AG (see “Alliance Advancing Unbranded Hyperimmune Globulin Product” ). Chinese trio join to develop antibody Shanghai Henlius Biotech Inc....
...at https://www.biocentury.com/coronavirus . Elizabeth S. Eaton, Staff Writer remdesivir, GS-5734 Gilead Sciences Inc. CSL Ltd. Takeda Pharmaceutical Co. Ltd. ADMA Biologics Inc. Shanghai Henlius Biotech Inc. covid-19 cov19count cov19count...
BioCentury | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

...first, the number of listings nearly doubled, despite a four-month lapse in new listings midyear. Shanghai Henlius Biotech Inc....
BioCentury | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

...2019 listings included CStone Pharmaceuticals Co. Ltd. (HKEX:2616), CanSino Biologics Inc. (HKEX:6185), Mabpharm Ltd. (HKEX:2181), Shanghai Henlius Biotech Inc....
BioCentury | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

...NASDAQ:HCM) said it would wait for better market conditions before moving forward with its application. Shanghai Henlius Biotech Inc....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Corp. (KOSDAQ:244460) 09/20/19 $25.4 $234.5 $218.3 -7% Exagen Inc. (NASDAQ:XGN) 09/18/19 $58.0 $168.5 $186.4 11% Shanghai Henlius Biotech Inc....
BioCentury | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

...of its proposed range. Parent company Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) said Shanghai Henlius Biotech Inc....
...development through IND submission to Phase III testing in combination with other agents. Hongjiang Li, Staff Writer Shanghai Henlius Biotech Inc. Programmed...
BioCentury | Sep 13, 2019
Financial News

Sept. 12 Financial Quick Takes: IPOs from 10x, SpringWorks; plus Shanghai Henlius, Fate and more

...Phase III testing for desmoid tumors. Hong Kong IPO could give Shanghai Henlius $3.7B valuation Shanghai Henlius Biotech Inc....
...June by Domain, Jean-Philippe Herbeuval, Kurma Partners, Idinvest Partners and Erganeo. BioCentury Staff 10x Genomics Inc. Fate Therapeutics Inc. Shanghai Henlius Biotech Inc. Kurma...
BioCentury | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

...Exchanges and Clearing Ltd., which operates the exchange. Shanghai Henlius refiles for Hong Kong IPO Shanghai Henlius Biotech Inc....
...of Oxford. A Phase I trial is slated for 2020. BioCentury Staff ADC Therapeutics S.A. Genmab A/S GNS Healthcare Inc. Shanghai Henlius Biotech Inc. SinoMab...
BioCentury | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

...Wave" ). Four other companies have active applications for listing on the biotech chapter including Shanghai Henlius Biotech Inc....
Items per page:
1 - 10 of 23